Different serum soluble Fas levels in patients with allergic rhinitis and bronchial asthma

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 54, Issue 12, 1999, Pages 1299-1302

  Kato, Masashi ^a   Nozaki, Y ^a   Yoshimoto, T ^b   Tamada, Y ^c   Kageyama, M ^d   Yamashita, T ^d   Kurimoto, F ^d   Nakashima, I ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUKYO HOSPITAL   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Allergic rhinitis; Bronchial asthma; Soluble Fas

Indexed keywords

FAS ANTIGEN;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIGEN EXPRESSION; ARTICLE; ASTHMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANTIGENS, CD95; APOPTOSIS; ASTHMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERSENSITIVITY, IMMEDIATE; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033394126     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.1999.00303.x     Document Type: Article

References (15)

1. 1. Trauth BC, Klas C, Peters AMJ, et al. Monoclonal antibody-mediated tumor regression by apoptosis. Science 1989;245:301-305.
2. 2. Cheng J, Zhou T, Liu C, Shapiro JP, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
3. 3. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994;37:1415-1420.
4. 4. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 1995;94:1-8.
5. 5. Natoli G, Ianni A, Costanzo A, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995;10:1157-1164.
6. 6. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995;154:2706-2713.
7. 7. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoictic human malignancy. Cancer Res 1996;56:3870-3874.
8. 8. Kato M, Hattori T, Ito H, et al. Serum soluble Fas levels as a marker to distinguish allergic and non-allergic rhinitis. J Allergy Clin Immunol 1999;103:1213-214.
9. 9. Kato M, Hattori T, Kato Y, Matsumoto Y, Yamashita T, Nakashima I. Elevated soluble tumor necrosis factor receptor levels in seasonal allergic rhinitis patients. Allergy 1999;54:278-282.
10. 10. Kato M, Hattori T, Kitamura M, Beppu R, Yanagita N, Nakashima I. Soluble ICAM-1 as a regulator of nasal allergic reaction under natural allergen provocation. Clin Exp Allergy 1995;25:744-748.
11. 11. Kato M, Hattori T, Ikeda R, et al. Amount of pollen has an effect on the systemic and local levels of soluble ICAM-1 in patients with seasonal allergic rhinitis. Allergy 1996;51:128-132.
12. 12. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-512.
13. 13. Hashimoto S, Imai K, Kohayashi T, et al. Elevated levels of ICAM-1 in sera from patients with bronchial asthma. Allergy 1993;48:370-372.
14. 14. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Medical Section of the American Lung Association. Ann Rev Respir Dis 1987;136:225-244.
15. 15. Kato M, Tamada Y, Kageyama M, et al. Elevated soluble Fas levels in herpes zoster patients. Br J Dermatol 1998;138:1091.